Antibody-drug conjugates have emerged as a promising cancer treatment, combining targeted delivery of cytotoxic agents with the specificity of monoclonal antibodies. Despite their potential, ADCs face ...

Several studies have generated CAR-T cells capable of producing bispecific T-cell engagers that can target a second antigen, thereby creating a localized OR gate CAR-T construct (67). The rationale ...